Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its …
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its …
Data presented at AAIC 2026 tie SEMA4D blockade to regulation of astrocyte biomarkers linked to disease progression, as …
The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase …
The Series A financing backs a monoclonal antibody licensed from a Chinese biotech, betting that blocking a different …
GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
The Coinbase CEO-backed longevity company will advance its epigenetic reprogramming mRNA medicine into Phase I trials for fatty …
The Alphabet-backed spinout of DeepMind’s AlphaFold programme has raised the largest private financing round in AI drug discovery …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to …
The British pharma giant’s third major deal of 2026 secures two FDA Breakthrough Therapy-designated kinase inhibitors and a …
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as …
Already a subscriber? Log in